Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma
Biomedical Chromatography · 2024-10 · 38 (10)
DOI: 10.1002/bmc.5986 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 13.08.2024. Verfasst von Esther M Hollander und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen.
Abstract (Originalsprache)
Small molecule inhibitors (SMIs) are increasingly being used in the treatment of non‐small cell lung cancer. To support pharmacokinetic research and clinical treatment monitoring, our aim was to develop and validate an ultra‐performance liquid chromatography–mass spectrometry (UPLC‐MS/MS) assay for quantification of eight SMIs: adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib. Development of the UPLC‐MS/MS assay was done by trying different columns and eluents to optimize peak shape. The assay was validated based on guidelines of the European Medicines Agency. Chromatographic separation was performed with a gradient elution using ammonium formate in water and methanol. Detection was performed using a triple quadrupole tandem mass spectrometer with electrospray ionization. Validation was performed in a range of 10–2500 μg/L for lorlatinib, 25–6250 μg/L for alectinib and crizotinib, 25–10,000 μg/L for capmatinib and selpercatinib, 50–12,500 μg/L for brigatinib, and 100–25,000 μg/L for adagrasib and sotorasib. Imprecision was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Esther M Hollander, Rob Ter Heine
Förderung
- Amgen
Zitieren
APA
Hollander, E. M., Zimmerman, N. M. C., Piet, B., van den Heuvel, M. M., Burger, D. M., Te Brake, L. H. M., & Ter Heine, R. (2024). Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma. Biomedical Chromatography, 38(10). https://doi.org/10.1002/bmc.5986
Vancouver
Hollander EM, Zimmerman NMC, Piet B, van den Heuvel MM, Burger DM, Te Brake LHM, et al. Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma. Biomedical Chromatography. 2024;38(10). doi:10.1002/bmc.5986
BibTeX
@article{Hollander2024,
author = {Hollander, Esther M and Zimmerman, Nachel M C and Piet, Berber and van den Heuvel, Michel M and Burger, David M and Te Brake, Lindsey H M and Ter Heine, Rob},
title = {Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma},
journal = {Biomedical Chromatography},
year = {2024},
volume = {38},
number = {10},
doi = {10.1002/bmc.5986}
}
EUVIMED